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Abstract
Purpose: Bioluminescence imaging is a powerful tool for studying gene expression and cell
migration in intact living organisms. However, production of bioluminescence by cells
transfected to express luciferase can be limited by the rate of plasma membrane transport of
its substrate D-luciferin. We sought to identify a plasma membrane transporter for D-luciferin that
could be expressed alongside luciferase to increase transmembrane ﬂux of its substrate and
thereby increase light output.
Procedures: Luciferase-expressing cells were transfected with a lentivirus encoding the rat reno-
hepatic organic anion transporter protein, Oatp1, which was identiﬁed as a potential transporter
for D-luciferin. Light output was compared between cells expressing luciferase and those also
expressing Oatp1.
Results: In two cell lines and in mouse xenografts, co-expression of Oatp1 with luciferase
increased light output by several fold, following addition of luciferin.
Conclusions: The increase in light output thus obtained will allow more sensitive detection of
luciferase-expressing cells in vivo.
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Introduction
Bioluminescence imaging is a versatile and widelyavailable method for imaging gene expression and cell
migration [1]. However, detection of cells expressing ﬁreﬂy
luciferase in vivo is limited by scattering and absorption of
the emitted light by proteins such as hemoglobin [2]. While
this is less of a problem at relatively superﬁcial body
locations, it can reduce both the sensitivity and resolution
with which internal organs and cell masses, such as early
stage tumors, can be imaged [3]. Various modiﬁcations have
been made to the luciferase reporter system to address this
problem, including the following: red-shifted luciferases and
luciferins, which show less light scattering [4–9], codon
optimization to increase luciferase expression [10], and
mutagenesis to increase enzyme stability [11] and activity
[12]. However, with some exceptions [6, 10, 12], the
majority of these strategies have not markedly increased
light output in vivo.
Numerous studies have indicated that luciferin transport
across the plasma membrane limits enzyme activity and
hence light output. In an early study, light output of
luciferase-expressing mammalian cells was increased by
reducing the number of membranes that luciferin had to
cross to reach the enzyme. This was achieved by removing
the peroxisomal targeting sequence found in the native
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enzyme, thus localizing it to the cytoplasm [13–15].
However, despite this modiﬁcation, the rate of luciferin
transport across the plasma membrane still limited light
output, with between 7 and 70 times more light produced by
lysed bacterial and mammalian cells [16, 17]. Light output
can also be increased by the addition of cell permeabilizing
agents such as DMSO, which increase luciferin uptake [15].
Increasing the lipid solubility and membrane permeability of
luciferin has also met with some success. For example,
bioluminescent output in intact cells, but not lysed cells, was
increased following incubation with a lipid-soluble ester
derivative of luciferin [18]. However, the aqueous solubility
of this substrate was much less than that of unmodiﬁed
luciferin, reducing the practicality of delivering it in vivo.
Amino-luciferin showed increased cell permeability in
comparison to D-luciferin [19], resulting in a peak photon
emission that was 25 % higher in vivo. However, the Vmax
of luciferase for this substrate is up to ten times lower than
for D-luciferin. Recent work has demonstrated that the cyclic
alkylaminoluciferin, CycLuc1, produces several-fold more
light than an equivalent dose of D-luciferin, providing greater
sensitivity of detection in the brain, where D-luciferin uptake
is low [20]. However, the ability of this substrate to give
greater sensitivity than D-luciferin in other tissues, when the
luciferin is used in its normal higher concentration range,
remains to be evaluated since it is not yet widely available.
Luciferin uptake varies between different cell types in
both plants and animals [21–24], and this has previously
been explained by the existence of luciferin exporters [25,
26], though it could also be explained by the existence of as
yet unidentiﬁed luciferin importers. A novel strategy to
increase luciferin uptake, and hence light output in lucifer-
ase-expressing cells, would be to co-express a luciferin
transporter together with luciferase. Although the existence
of luciferin importer proteins has been inferred [27], to the
authors’ knowledge, no importers of luciferin have been
deﬁnitively identiﬁed. Bio-distribution studies have shown
that luciferin concentrations are high in the liver and kidneys
following intravenous and intraperitoneal injections in mice
[21, 23], implying the presence of a protein or proteins that
mediate luciferin uptake. The family of organic anion
transporting polypeptides (OATP), of which rat (Rattus
norvegicus) Oatp1 (also known as Slc21a1, Slco1a1), was
the ﬁrst member to be identiﬁed [28, 29], has over 60
members, which are expressed predominantly in the liver
and kidneys and are responsible for the removal of a broad
range of organic molecules from the blood, including
xenobiotics, hormones, and toxins [30–32]. Among Oatp1’s
substrates and inhibitors are organic anions and cations,
many of which are, like D-luciferin [33], cyclic, polycyclic,
or heteropolycyclic carboxylic acids [30, 34, 35].
The observation that Oatp1 has a broad range of
substrates, the correlation between the location of Oatp1
expression and high luciferin uptake, and the resemblance of
D-luciferin to some known substrates of Oatp1 suggested to
us that expression of this transporter might facilitate cellular
luciferin entry and thus enhance bioluminescent output. We
found recently, when investigating Oatp1 as a potential gene
reporter for use with magnetic resonance imaging (MRI) and
single-photon emission computed tomography (SPECT)
[36], that Oatp1 expression increased bioluminescence from
cells expressing luciferase in vivo. We show here that this
can be explained by Oatp1-mediated uptake of D-luciferin,
which signiﬁcantly enhances the sensitivity of this widely
used gene reporter system.
Materials and Methods
Vectors
LV-PGK-SO, comprising a sequence encoding mStrawberry [36],
E2A (QCTNYALLKLAGDVESNPGP) [37], and Oatp1 (kindly
provided by Dr Allan Wolkoff, [GenBank: NM_017111.1]), with a
stop codon at the end of Oatp1, was cloned into the lentiviral
transfer plasmid pBOBI (Inder M. Verma laboratory, Salk Institute,
California) downstream of a PGK promoter [38]. The control vector
(referred to as LV-PGK-ST) contained Timd2 [Genbank:
NM_001161356.1] in place of the Oatp1 sequence. Replication
defective vesicular stomatitis virus glycoprotein (VSV-G)
pseudotyped lentiviral vectors were produced [39] and puriﬁed
[40] according to published protocols, using the transfer plasmids
and three packaging plasmids (Inder M. Verma laboratory, Salk
Institute, CA). Inducible plasmids were produced using a doxycy-
cline responsive promoter (TRE3G) and the mStrawberry-E2A-
Oatp sequence described above (referred to as pTRE3G-SO).
Plasmid maps of these vectors are shown in additional ﬁles.
Cell Culture
Human embryonic kidney cells (HEK 293T) were acquired from
Thermo Scientiﬁc (Loughborough, UK), Lewis Lung murine
carcinoma (LL2) cells from the American Type Tissue Collection
(ATCC, Teddington, UK), and HCT 116 cells from LGC
Promochem. HEK 293T and LL2 cells were grown in DMEM
(Invitrogen, UK), supplemented with 10 % fetal bovine serum
(FBS), 2 mM L-glutamine and 0.1 mM MEM nonessential amino
acids. HCT 116 cells were grown in McCoy's 5A media with
Glutamax (Invitrogen), supplemented with 10 % FBS. Cells were
mycoplasma tested upon receipt.
Cell Transfection and Transduction
Stable luciferase-expressing HEK 293T cells used to validate Oatp1
function were generated by transduction with a FIV-based vector
[41] modiﬁed to encode a Luc2-YFP fusion protein (LHLY) under
a CAGGS promoter and clones selected using hygromycin. LL2
cells were transfected with a pBluescript plasmid encoding
luciferase under a CAGGS promoter. Stable Oatp1 (and control)
expressing subclones were generated from the above by lentiviral
transduction with LV-PGK-SO (and LV-PGK-ST) and dilution
cloning. Transgene expression post-transduction was conﬁrmed by
Western blot and by ﬂow cytometry (FACSCalibur II, BD
Biosciences, CA, USA) or ﬂuorescence imaging (IVIS 200 series
camera; PerkinElmer) or by microscopy. The doxycycline-
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inducible mStrawberry-E2A-Oatp1 and luciferase-E2A-Oatp1 plas-
mids used for bioluminescence experiments in vitro were con-
structed using a modiﬁed TRE3G vector (Clontech) containing a
puromycin resistance cassette for selection of stable clones.
Western Blots
Cells were extracted using M-Per reagent (Thermo Scientiﬁc) with
Complete Mini Protease inhibitors (Roche), and protein concentra-
tion determined using the Bradford assay. Extracts were run on an
SDS PAGE gel (NuPAGE, Invitrogen), transferred to a nitrocellu-
lose membrane and luciferase-YFP detected using polyclonal goat
anti-luciferase antibody (g475A, Promega), at 1 in 25,000 dilution
with incubation for 1 h at room temperature. For α-tubulin staining
a monoclonal mouse anti-α-tubulin (T1799, Sigma-Aldrich) was
used at 1 in 1,000 dilution with overnight incubation at 4 °C. For
mStrawberry staining, rabbit polyclonal anti-RFP (ab34771,
AbCam) was used at 1 in 10,000 dilution with overnight incubation
at 4 °C. Horseradish peroxidase conjugated anti-rabbit (111-035-
003), anti-goat (705-035-003-JIR), and anti-mouse (115-035-006-
JIR) antibodies (Jackson ImmunoResearch, Suffolk, UK) were used
as the secondary antibodies at 1 in 10,000 dilution with an
incubation time of 45 min at room temperature. All antibodies
were diluted with 5 %w/v milk powder and 0.1 % Tween.
Imaging
Cells were grown to 70 % conﬂuence in six-well tissue culture
plates (Nunc, Thermo Scientiﬁc) and then imaged using an IVIS
200 series camera (PerkinElmer) with small binning, a 1 s
exposure, and an F-stop between 1 and 4, immediately after
addition of luciferin to the growth medium (10 to 150 μg/ml;
PerkinElmer). The ﬁnal cell counts per well were typically between
2 and 3 million. For time course experiments (Figs. 1c, d, 3c, and
4a), measurements were repeated every minute for 20 min after
luciferin addition. The number of cells per well was counted using
a Z2 Cell and Particle Counter (Beckman-Coulter). The biolumi-
nescence, expressed as photons/s/cell, was calculated for each well
Fig. 1 Oatp1 expression enhances bioluminescent output of luciferase-expressing cells. a HEK 293T cells expressing
luciferase were transduced with a lentiviral vector expressing either Oatp1 or Timd2 (control) or were not transduced (control),
24 h before incubation with luciferin. Oatp1-expressing cells emitted significantly more light than control cells immediately after
luciferin addition (1-s exposure time; n=3, two-tailed T test). b Lewis lung carcinoma cells (LL2) expressing luciferase were
transduced with lentiviral vectors, as described in (a). Clonal HEK 293T cells expressing Oatp1 produce more light than the
luciferase-expressing cell population from which they were derived, for a period of 20 min following addition of luciferin at a
concentration of c 36 μΜ and d 535 μM (n=3, error bars show SD). e Western blot of protein extracts from the cells used in c
and d, showing luciferase-YFP and RFP expression in control HEK 293T cells and HEK 293T cells transduced to express
Oatp1. The presence of RFP indicates expression of the mStrawberry-Oatp1 transgene. sr steradian.
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by dividing the photon count at each time point by the cell count
for that well and an average calculated for four wells per condition.
Inhibition experiments were performed by pre-mixing growth
medium with quinine, at a concentration of 1 mM, and replacing
the standard growth medium with this medium 5 min prior to
addition of luciferin. Cell extracts were obtained by suspending 2×
107 cells in 1 ml of extraction buffer (100 mM potassium
phosphate, pH 7.8, 1 mM dithiothreitol) [16], and freeze thawing
three times on dry ice. The extract was mixed 2:1 with 3× assay
buffer (25 mM glycylglycine buffer, pH 7.2, 5 mM ATP, and
15 mM MgSO4) [16] that had been premixed with luciferin. The
number of photons per well was recorded at each time point using
Living Image software (PerkinElmer). For imaging in vivo,
xenograft-bearing mice were injected intraperitoneally with
150 mg/kg of luciferin and imaged every minute between 5 and
20 min post injection.
Doxycycline Induction
Doxycycline was prepared as a stock solution of 10 mg/ml in water,
sterile ﬁltered, and stored at 4 °C. An appropriate volume of the
stock solution was added to growth medium 24 h prior to imaging,
to produce the ﬁnal concentrations indicated in Figs. 3 and 4.
Imaging of these cells was performed as described above.
Statistical Analyses
Student’s T test and linear regression were performed using Excel
(Microsoft) and Graphpad Prism (Graphpad Software Inc.) soft-
ware. Unequal variance T tests were used when variance between
groups were dissimilar. No blinding or randomization was used in
any of the experiments, and no animals were excluded from
analyses.
Animals
Female SCID mice were obtained from Charles River (UK) at
~20 g (2 to 3 months) each and used within a few months of
acquisition. Animals were injected subcutaneously with 1×107
viable HEK 293T cells per ﬂank and anesthetized using 2 %
isoﬂurane in 75 % air/25 % O2 (ﬂow rate 2 l/min) for
bioluminescence and ﬂuorescence imaging. Animal experiments
were carried out under the authority of project and personal licenses
issued by the Home Ofﬁce, UK and were approved by the Cancer
Research UK, Cambridge Institute Animal Welfare and Ethical
Review Body.
Results
Oatp1 Expression Enhances Bioluminescence
A lentiviral vector (LV-PGK-SO) expressing the red
ﬂuorescent protein (RFP) mStrawberry and Oatp1 from the
PGK promoter was constructed. The coding sequences of
the two proteins were separated by an E2Asequence, which
results in equimolar expression from the same transcript [42]
(see Figure S1). Human embryonic kidney (HEK 293T)
cells stably expressing a luciferase-YFP fusion protein [36],
were transduced, at a multiplicity of infection of 2, with LV-
PGK-SO, or with a control lentivirus, LV-PGK-ST, in which
the coding sequence for Oatp1 was replaced with that of
Timd2 [43]. Timd2 is a receptor that mediates H-ferritin
endocytosis, and like Oatp1, is expressed on the plasma
membrane in liver and kidney cells. Nontransduced cells
were used as a further control. Expression of Oatp1, in cells
transduced with LV-PGK-SO, and of Timd2, in cells
transduced with LV-PGK-ST, was conﬁrmed by observa-
tions of ﬂuorescence from the co-expressed mStrawberry
and by detection of mStrawberry on western blots. Cells
expressing Oatp1 showed signiﬁcantly higher initial rates of
photon production per cell (three to sixfold), over a range of
D-luciferin concentrations, when compared with cells ex-
pressing Timd2 or non-transduced cells (Fig. 1a), despite
equivalent levels of luciferase expression. Comparison of
cells expressing Timd2, non transduced cells and cells
expressing Oatp1, using two-way ANOVA, showed that
Oatp1 expression accounted for 57.8 % of the variation and
D-luciferin concentration for 32.5 %, with 9.1 % interaction
(pG0.0001). In a comparison of the control groups,
expression of Timd2 had no effect on light output (two-
way ANOVA, p=0.5526), with D-luciferin concentration
accounting for 86 % of total variation (pG0.0001) and
Timd2 expression accounting for 0.04 %. The greatest
increase in light output with Oatp1 expression, over sixfold,
was observed at the lowest D-luciferin concentrations, the
enhancement correlating negatively with D-luciferin concen-
tration (Fig. 1a, b, c, d). Similar results were obtained with
Lewis lung carcinoma (LL2) cells (Fig. 1b). There was a
4.5- to 6.2-fold increase in photon emission from LL2 cells
expressing Oatp1, when compared to control cells. The
enhancement again correlated negatively with D-luciferin
concentration. Light output from Oatp1-expressing cells at
10 μg/ml of D-luciferin was 2.8× higher when compared to
control cells incubated with 100 μg/ml (Fig. 1b). Quinine, an
inhibitor of Oatp1 [35], decreased the light output of Oatp1-
expressing HEK 293T cells to a level comparable with that
of control cells incubated with the inhibitor (Fig. 1a).
Expression of Oatp1 led to sustained enhancement of
bioluminescence following addition of 36 (10 μg/ml)
(Fig. 1c) or 535 μΜ (150 μg/ml) luciferin (Fig. 1d) to
luciferase-expressing HEK 293T cells that had been sub-
cloned following transduction with the LV-PGK-SO vector.
The usual burst kinetics associated with luciferase expres-
sion [16] were evident and were exaggerated by expression
of Oatp1. Average light output from Oatp1-expressing cells
was between 2.6- and 5.6-fold higher than control cells over
the 20 min following luciferin addition. Expression of Oatp1
was conﬁrmed by western blotting, which showed the
presence of co-expressed mStrawberry (RFP). These blots
also showed that luciferase-YFP was expressed equally in
Oatp1-expressing and control cells (Fig. 1e).
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Effect of Oatp1 Expression on the Kinetics
of Photon Emission
Lineweaver-Burk plots of the initial rates of photon emission
per cell (Fig. 2a, b) gave an apparent Km of luciferase for
luciferin (Km (D-luciferin)) of 422 μM in control HEK 293T
cells and 166 μM in cells expressing Oatp1. The Km in cell
extracts was 57 μM. The apparent Km (D-luciferin) in LL2
cells was 114 μM in control cells and 71 μM in cells
expressing Oatp1. Expression of Oatp1 increased Vmax in
HEK 293T cells from 23,955±5,791 to 58,770±4,134
photons/s/cell (pG0.05) and from 84±4 photons/s/cell to
Fig. 2 Effect of Oatp1 expression on the kinetics of photon production. Lineweaver-Burk plots showing the effects of Oatp1
expression and luciferin concentration on light output from a HEK 293T cells and b LL2 cells expressing luciferase-YFP. The
data were taken from Fig. 1a, b.
Fig. 3 Oatp1 expression levels correlated linearly with enhancement of bioluminescence. HEK 293T cells expressing
luciferase-YFP were transfected with a plasmid vector co-expressing mStrawberry and Oatp1 under the control of a
doxycycline-inducible promoter (pTRE3G-SO). a Western blot showing induction of mStrawberry (RFP), and hence Oatp1, at
increasing doxycycline concentrations. b The RFP band intensity on the western blot, when expressed as a ratio of the α-
tubulin band intensity, showed a linear dependence on doxycycline concentration. c Enhancement of bioluminescence,
following addition of luciferin (89 μM), was linearly dependent on the doxycycline concentration used to induce Oatp1
expression. d Enhancement of bioluminescence (c) versus Oatp1 expression (intensity of mStrawberry/α-tubulin on the
Western blot (b)). All measurements were made 24 h after the addition of doxycycline to the cell culture medium.
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402±17 photons/s/cell in LL2 cells (pG0.01). These data
conﬁrm that cell uptake of luciferin is rate limiting for
luciferase activity.
Oatp1 Expression Correlates Linearly
with Enhancement of Bioluminescence
The relationship between Oatp1 expression and enhance-
ment of light output was further investigated in luciferase-
YFP-expressing HEK 293T cells that had been stably
transfected with a plasmid containing a doxycycline-
inducible promoter driving expression of the
mStrawberry-E2A-Oatp1 transgenes (pTRE3G-SO, see
Supplementary Data File). There was a linear relationship
between doxycycline concentration and an increase in
Oatp1 expression, as determined from the levels of co-
expressed mStrawberry on Western blots (Fig. 3a, b). Western
blotting also showed that there was no change in the expression
of luciferase-YFP with increasing doxycycline concentration
(Fig. 3a). There was also a linear relationship between
doxycycline concentration and enhancement of biolumines-
cence (Fig. 3c) and thus between bioluminescence enhance-
ment and Oatp1 expression (Fig. 3d).
Similar experiments were performed in which both lucifer-
ase and Oatp1 were co-expressed from a doxycycline-inducible
promoter (Fig. 4). HEK 293T and HCT116 cells were stably
transfected with pTRE3G-LO (see Supplementary Data File),
in which the luciferase and Oatp1 coding sequences were
separated by an E2A sequence [37]. In both cell lines photon
emission was correlated with the concentration of doxycycline
used to induce gene expression (Fig. 4a). Induction of both
luciferase and Oatp1 was conﬁrmed by measurements of
increased luciferase expression on Western blots (Fig. 4b, c).
Increased light output appeared to correlate linearly with Oatp1
expression in HEK 293T cells; however, there was some
evidence of nonlinearity in HCT116 cells (Fig. 4a). This may
be due to variation in expression of luciferin exporter proteins
of the ABCG2 or BCRP families [24, 25], or constitutive
OATP1B3 expression in HCT116 cells [44].
Oatp1 Expression Increased Bioluminescence
In Vivo
We have demonstrated previously that Oatp1 expression
increases light output in vivo [36]. Control HEK 293 T cells
(1×107) expressing luciferase-YFP (the same clone as used
in Fig. 1) were implanted in the left ﬂank of SCID mice, and
1×107 of the same cells, which had transduced with a
lentiviral vector expressing Oatp1 and mStrawberry and then
cloned (shown in Fig. 1c, d, e), were implanted in the right
ﬂank (n=5). Animals were imaged every minute between 5
and 20 min following intraperitoneal injection of luciferin
(150 mg/kg). A representative bioluminescence image from
a mouse at day 15 post implantation is shown in Fig. 5a.
Corresponding ﬂuorescence images showed that luciferase-
YFP was expressed equally in the contralateral xenografts.
Light output from xenografts expressing Oatp1 in ﬁve
different animals, averaged over 15 min following luciferin
injection, was between ~5 and up to 20-fold higher than the
corresponding contralateral control xenografts for up to
18 days post implantation of the cells (see Fig. 5b) [36].
Given the negative correlation between bioluminescence
enhancement and D-luciferin concentration observed in the
cell experiments this wide variation in enhancement ob-
served in vivo may reﬂect differences in the delivery of
luciferin to the tissue. The previous studies, in which we
investigated the use of Oatp1 as a gene reporter for MRI and
Fig. 4 Co-induction of luciferase and Oatp1 expression
correlates with enhancement of bioluminescence. HEK
293T and HCT116 cells were transfected with a plasmid
(pTRE3G-LO) expressing luciferase and Oatp1 from a doxy-
cycline-inducible promoter. a Enhancement of biolumines-
cence, following addition of luciferin (89 μΜ), was dependent
on the doxycycline concentration used to induce expression
(n=3, error bars show SD). Western blot showing induction of
luciferase, and hence Oatp1, at increasing doxycycline
concentrations in b HEK 293T cells and c HCT116 cells.
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for SPECT, demonstrated that Oatp1 expression, at the
levels used here, had no measureable effect on cell growth in
vitro [36]. Additionally, the ability of HEK 293T cells to
form xenografts and their subsequent growth in vivo was not
inﬂuenced by Oatp1-expression. There was no signiﬁcant
difference in the weights of excised control and Oatp1-
expressing HEK 293T xenografts 24 days after cell
implantation (n=5, two-tailed paired T test, p=0.13) (see
Fig. 5c).
Discussion
A major limitation of luciferase as a reporter gene has been
identiﬁed as the rate of luciferin uptake into cells [15]. This
has been addressed previously by lowering pH, so that
luciferin becomes protonated and more membrane-soluble,
or by adding DMSO to permeabilize the plasma membrane.
However, these approaches damage cell viability [15] and
cannot be used in vivo, in an intact animal. Another
approach has been to develop synthetic luciferins with
increased membrane permeability [20]. We have addressed
this problem here by identifying a plasma membrane
transporter for luciferin, which when expressed with lucif-
erase enhances light output by several-fold. Our approach
would also be compatible with other approaches that have
been used to improve light output, such as codon
optimization and red-shifting of the emitted spectrum [6,
10], as well as future gains in light output that might be
achieved by directed evolution of the enzyme. However, it
should be noted that the enhancement of light output will
likely be inﬂuenced by a number of factors in addition to the
levels of Oatp1 transgene expression, including luciferin
concentration, the stage of xenograft development, and the
endogenous levels of expression of luciferin importers, such
as Oatp1 [29–32], and also exporters [25, 26].
The enhancement demonstrated here should facilitate
bioluminescent detection of labeled cells in situations where
bioluminescent output is low, for example, when there are
few labeled cells or they are located at a greater tissue depth.
For example, detection of the very earliest stages of
tumorigenesis in mouse models of cancer following the
implantation of small numbers of tumor stem cells or the
early stages of autochthonous tumor development following
the transformation of somatic cells using viral vectors [45].
Enhanced light output could also increase the sensitivity of
detection of gene expression in regions where luciferin
uptake is low, such as the brain [21, 23] and detection of
luciferase expression when relatively weak promoters are
used. The latter problem has been addressed previously by
using a two-step transcriptional ampliﬁcation (TSTA)
system [46–48]. This system, together with the one
described here, could further improve light output and the
Fig. 5 Oatp1 expression increases luciferase bioluminescence in vivo. a Representative mouse showing increased
bioluminescence from the Oatp1-expressing HEK 293T xenograft (right flank), when compared with the control xenograft,
expressing luciferase-YFP alone (left flank). YFP fluorescence demonstrated that luciferase was equally expressed in both
xenografts. b Enhancement of light output of individual Oatp1-expressing xenografts relative to the contralateral control
xenograft. Points show the ratio of the mean light output between 5 and 20 min following luciferin injection, for up to 18 days
post cell implantation. Error bars show±SD. At the 18 day time point, the light outputs of the Oatp1-expressing and control
xenografts were normalized to the respective weights of the excised tissues at 24 days post cell implantation. Light output was
significantly greater at all time points in Oatp1-expressing xenografts compared to control xenografts (n=5, paired one-tailed T
test), pG0.05 for all time points. cWet weight of excised control and Oatp1-expressing HEK 293 T xenografts 24 days after cell
implantation.
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sensitivity of detection of weak promoter activation. Co-
expression of Oatp1 could also be used to reduce the amount
of luciferin required.
Bioluminescence measurements on tumor cells express-
ing luciferase in vivo have been used to assess response to
new therapeutic drugs [49]. Since Oatp1 is known to
transport a wide range of different molecules, its potential
to transport the drug molecule under investigation would
need to be considered when assessing the pharmacodynamic
properties of the drug.
Conclusions
We demonstrated recently that, by transporting a clinically
approved hepatotropic contrast agent, Oatp1 can be used as a
gene reporter for MRI and that by exchanging the Gd3+ ion
in this contrast agent for 111In, can be used with SPECT as
well [36]. Together with its capability to increase luciferase-
dependent bioluminescence, this makes Oatp1 a very
versatile system for imaging gene expression in vivo.
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